KY
KYTX.US Kyverna Therapeutics, Inc. Common Stock
- Market cap
- USD 319M
- P/E
- -
- P/B
- 2.40x
- ROE
- -120.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KYTX.US undervalued?
Graham numberThe Graham number of Kyverna Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kyverna Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Kyverna Therapeutics, Inc. Common Stock yet.
Kyverna Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CA…
Full company profileKyverna Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kyverna Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 5.66M | 7.03M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.66M | 7.03M | -1.71M | -2.13M | -1.80M | - |
| Operating Income | -26.3M | -29.4M | -62.4M | -143M | -170M | -165M |
| EBITDA | -25.8M | -27.8M | -58.5M | -125M | -159M | -156M |
| Net Income | -26.4M | -28.9M | -60.4M | -127M | -161M | -160M |
| EPS | -1.02 | -0.67 | -1.40 | -3.33 | -3.64 | -2.58 |
| Balance Sheet | ||||||
| Total Assets | 85.5M | 66.9M | 75.2M | 305M | 294M | 189M |
| Total Liabilities | 132M | 141M | 26.0M | 38.1M | 61.6M | 56.3M |
| Shareholders' Equity | -46.3M | -74.0M | 49.2M | 267M | 232M | 133M |
| Cash & Short-term Investments | 76.1M | 51.3M | 57.5M | 286M | 279M | 171M |
| Total Debt | 5.56M | 10.6M | 9.08M | 8.24M | 29.0M | 32.5M |
| Cash Flow | ||||||
| Operating Cash Flow | -22.2M | -36.1M | -52.4M | -114M | -154M | -156M |
| Capital Expenditure | 1.29M | 768K | 621K | 2.21M | 5.00K | 623K |
| Free Cash Flow | -23.4M | -36.9M | -53.0M | -116M | -154M | -157M |
| Ratios | ||||||
| ROE | - | - | -122.8% | -47.8% | -69.4% | -120.1% |
| ROA | -30.8% | -43.2% | -80.3% | -41.8% | -54.9% | -84.5% |
| Net Profit Margin | -465.9% | -411.3% | - | - | - | - |
| Debt to Equity | - | - | 0.18x | 0.03x | 0.12x | 0.24x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kyverna Therapeutics, Inc. Common Stock dividends
Kyverna Therapeutics, Inc. Common Stock has not paid dividends in the last 5 fiscal years.
Who owns Kyverna Therapeutics, Inc. Common Stock
- Insiders 7.68%
- Institutions 79.14%
- Public & others 13.18%
- Shares outstanding 63.2M
- Free float 36.9M
Top funds holding KYTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| MEDICAL BioHealth EUR Acc | 1.76M | 2.82% | +0.02% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.57M | 2.51% | +11.95% | Sep 2026 |
| iShares Russell 2000 ETF | 1.08M | 1.73% | 0.00% | Oct 2026 |
| T. Rowe Price Health Sciences | 857K | 1.37% | 0.00% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 507K | 0.81% | +0.27% | Oct 2026 |
| Fidelity Small Cap Index | 460K | 0.74% | +0.28% | Aug 2026 |
| apo Medical Opportunities R | 369K | 0.59% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 352K | 0.56% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 294K | 0.47% | -0.19% | Oct 2026 |
| Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 260K | 0.42% | +0.08% | Oct 2026 |
| Vanguard Russell 2000 ETF | 244K | 0.39% | +1.29% | Sep 2026 |
| Galileo - Biotech Innovation Fund S USD | 205K | 0.33% | +86.36% | Apr 2026 |
| Schwab US Small-Cap ETF™ | 192K | 0.31% | +0.23% | Oct 2026 |
| RIM Global Bioscience EUR | 189K | 0.30% | +45.46% | Jul 2026 |
| Simplify Propel Opportunities ETF | 183K | 0.29% | 0.00% | Oct 2026 |
| Nuveen Equity Index R6 | 178K | 0.28% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 177K | 0.28% | +51.91% | Sep 2026 |
| WesMark Small Company Fund | 166K | 0.27% | +50.77% | Sep 2026 |
| iShares Micro-Cap ETF | 126K | 0.20% | 0.00% | Oct 2026 |
| Bridgeway Ultra-Small Company | 112K | 0.18% | 0.00% | Jun 2026 |
Top institutions holding KYTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| GordonMD Global Investments LP | 4.24M | 6.79% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.13M | 5.01% | +257.41% | Jun 2026 |
| Bain Capital Life Sciences Investors, LLC | 2.89M | 4.61% | -7.23% | Jun 2026 |
| AIGH Capital Management, LLC | 2.80M | 4.47% | +39.79% | Jun 2026 |
| Deerfield Management Co | 2.00M | 3.20% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.90M | 3.03% | +6.40% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.19M | 1.90% | -23.74% | Jun 2026 |
| Geode Capital Management, LLC | 1.05M | 1.68% | +147.61% | Jun 2026 |
| INSIGHT HOLDINGS GROUP, LLC | 989K | 1.58% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 982K | 1.57% | +0.51% | Jun 2026 |
| State Street Corp | 982K | 1.57% | +610.22% | Jun 2026 |
| Propel Bio Management LLC | 883K | 1.41% | +37.05% | Jun 2026 |
| Woodline Partners LP | 845K | 1.35% | 0.00% | Jun 2026 |
| Millennium Management LLC | 640K | 1.02% | -36.37% | Jun 2026 |
| MBB PUBLIC MARKETS I LLC | 614K | 0.98% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 500K | 0.80% | 0.00% | Jun 2026 |
| D. E. Shaw & Co LP | 469K | 0.75% | -34.96% | Jun 2026 |
| Wells Fargo & Co | 373K | 0.60% | +226.06% | Jun 2026 |
| UBS Group AG | 366K | 0.58% | -18.72% | Jun 2026 |
| The Goldman Sachs Group Inc | 335K | 0.54% | +57.45% | Jun 2026 |
Kyverna Therapeutics, Inc. Common Stock company profile
- Company name
- Kyverna Therapeutics, Inc. Common Stock
- Ticker
- KYTX.US
- Exchange
- USA Stocks
- Listed since
- Feb 8, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 172
- Fiscal year end
- December
- Address
- 5980 Horton Street, Emeryville, CA, United States, 94608
- Phone
- 510 925 2492
- Website
- kyvernatx.com
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Kyverna Therapeutics, Inc. Common Stock management
10- Ms. Christi L. ShawExecutive Chairperson · born 1967
- Mr. Warner BiddleCEO & Director · born 1967
- Dr. Naji H. Gehchan M.B.A., M.D.Chief Medical & Development Officer · born 1982
- Mr. Gregory MartiniChief Financial Officer · born 1989
- Dr. Tom Van Blarcom Ph.D.Senior VP & Head of Research
- Mr. Mayo PujolsChief Technology Officer · born 1970
- Ms. Jessica SerraHead of Investor Relations
- Mr. Ritesh SrivastavaChief Legal & Compliance Officer
- Ms. Tracy RossinSenior Vice President of Corporate Affairs · born 1977
- Mr. Dan MaziaszChief Business Officer